1875 South Grant Street
About Medeor Therapeutics
MEDEOR THERAPEUTICS is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies. Our growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Our pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). We hold exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.
4 articles with Medeor Therapeutics
TrakCel to develop and supply Medeor Therapeutics with cellular supply chain management and orchestration system
TrakCel, the cell and gene therapy supply chain tracking and orchestration system software developer, today announces it has been engaged to build a custom-configured system for Medeor Therapeutics.
Appointed Iqbal Husain, Ph.D., as its Senior Vice President, Program Management, and Michael Zdanowski as its Vice President, Biopharmaceutical Operations.
The award is to support a Phase 3 clinical trial to evaluate the safety and efficacy of MDR-101.
Medeor Receives FDA Clearance Of IND Application And Special Protocol Assessment For Pivotal Clinical Study Of MDR-101